Metabolic factors may increase risk of dying from prostate cancer

Share this content:

The risk of dying from prostate cancer is increased by metabolic syndrome, whose characteristics include high blood pressure (BP), blood sugar, blood lipids, and body mass index (BMI). The results of this study suggest that public health recommendations regarding diet and lifestyle to prevent heart disease and diabetes may also decrease a man's likelihood of dying from prostate cancer.

Previously, researchers had little knowledge about possible links between metabolic factors and men's risk of a diagnosis of or dying from prostate cancer. This study analyzed data from 289,866 men enrolled in the Metabolic Syndrome and Cancer Project.

During the average follow-up time of 12 years, prostate cancer was diagnosed in 6,673 men and 961 died from the disease. The risk of dying from prostate cancer was increased by 36% for those in the highest BMI category and by 62% for those in the highest BP category. Further, when a composite score of all metabolic factors was compared, men with a high score were more likely to die from prostate cancer.

No evidence was found for a link between high levels of metabolic factors and a man's risk of developing prostate cancer. A link was revealed between these factors and risk of dying from the disease. These findings suggest that while men with metabolic syndrome are not more likely than others to develop prostate cancer, if they do develop it, they are more likely than other men to die from it.

“These observations suggest that cardiovascular risk factors such as overweight and hypertension are involved in stimulating the progression of prostate cancer,” said Pär Stattin, MD, PhD, a visiting scientist at Memorial Sloan-Kettering Cancer Center in New York City.

This study was published in Cancer (2012; doi:10.1002/cncr.27677).
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs